Navigation Links
Fox Chase researchers identify new mechanism used by cells to reverse silenced genes
Date:6/30/2011

PHILADELPHIA (June 30, 2011)Scientists at Fox Chase Cancer Center have discovered a new mechanism used by cells in the body to turn on silenced genes. This process is critical in preventing the development of cancersuggesting the possibility of new therapies that might target the specific changes underlying the disease. The findings will be published online in the journal Cell on June 30, 2011.

The process investigated by Alfonso Bellacosa, M.D., Ph.D., Associate Professor at Fox Chase, and his colleagues, is called methylation, in which the cell chemically tags genes to turn them off. More specifically, the cell silences a gene by adding a chemical compound known as a methyl group; without that methyl group, the gene remains active.

It's a process of great interest to scientists, Bellacosa explains, because methylation is a key part of normal gene regulation but, when it silences the genes that normally suppress tumors, it results in cancer. Indeed, some cancer drugs work by demethylatingmeaning, removing methyl groups from DNA. But those drugs will demethylate DNA non-specifically, he says, causing side effects and other problems.

Scientists have been investigating for years how the cell adds methyl groups to genes to turn them off, but have been less clear about the process of demethylation. For instance, some have suspected that demethylation only occurs passively, such as when DNA with an attached methyl group replicates, creating new DNA without a methyl group.

Now, Bellacosa and his team present the first direct evidence that demethylation can be, in fact, an active process, controlled by a specific protein along with clues about how to act on it in a targeted way.

The researchers found that one protein called thymine DNA glycosylase or TDGknown to help repair DNAis also responsible for removing methyl groups from DNA. Studies with mice that lacked TDG activity indicated the gene was needed for survival. Looking closer at the mouse embryos that didn't survive, they saw that the methylation was all awry genes that would normally be demethylated weren't, and remained silenced.

TDG needs a second protein to demethylate DNA, says Bellacosa - so future therapies might be devised to direct this machinery to turn on specific anti-cancer genes, for instance. "Since we now know there are proteins that actively affect demethylation, then we can imagine a new type of cancer therapy that demethylates specific genes. We would have a more precise and more targeted type of therapy."

What's also exciting, explains Bellacosa, is the discovery that the cell uses tools that normally repair DNA for a very different purpose: reversal of gene silencing by demethylation. "It's a totally new concept that DNA repair has this additional new function."

Beside cancer, this knowledge may also be applied to other diseases with alteration of methylation. He cautions, however, that scientists still have not figured out how to target therapy to specific genes, so any benefits to this discovery are years away. "This is a very fundamental study that gets at the process by which genes are turned on or turned off," he says. "We may be several years away from taking full advantage of this new knowledge. But we will get there."


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Hollywood-Style Liposuction Comes to DC: Chevy Chase Smartlipo Brings Revolutionary Laser-Assisted Liposuction to DC Metro Area
2. Torchmark Corporation Declares Dividend and Resumes Stock Repurchases
3. International Merchant Advisors to Complete Purchase of Medical Marijuana Company Organic Science, Inc.
4. Grand Opening of LIFE Ionizer Australia Launches with a Free Ionizer Upgrade with Purchase of Alkaline Water Ionizer from LIFE Ionizer Australia
5. A New Twist On Convert to Purchase
6. Ensemble Healthcare Properties Purchases North Valley Medical Plaza
7. ARI Purchases Intercytex Assets
8. CapSite™ Provides Detailed Transparency on Healthcare Technology Purchases
9. Ivory Homes Plans Ahead for the April 30th Home Buyer Tax Credit Deadline with 100 New Homes Ready for Quick Purchase
10. R-Biopharm Group Purchases a Majority Ownership in Trilogy Lab, Expanding US Operations
11. Fox Chase clinical trial tests first of its kind antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... 2017 , ... Hernandez Insurance Agencies, a northern Virginia firm ... DC region, is inaugurating a “New Leash On Life” charity initiative in conjunction ... to be companions for veterans in need. , The Semper K9 organization works ...
(Date:8/18/2017)... ... , ... The Brian Gifford Agency, an Indiana-based firm providing asset protection and ... Academy in a charity drive to provide for at-risk children and teens in the ... is a nonprofit organization that has offered critical programs to at-risk and foster children ...
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 ... bioidentical hormone replacement therapy and integrative medicine, has become a frontrunner for people ... such as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in ...
(Date:8/18/2017)... Vermont (PRWEB) , ... August 18, 2017 , ... ... phone numbers and call tracking and monitoring solutions, announced today the launch of ... site include a modern navigation and aesthetic, fully responsive design, and an enhanced ...
(Date:8/18/2017)... ... 18, 2017 , ... “Beyond Our Imaginations: The Infinite God”: shows the importance ... God” is the creation of published author, Mark Lawrence, born in Michigan, the author ... problem with becoming a greater man of God is that I have to be ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... 17, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... health and big data solutions, announced today that ... and non-U.S. investors for the sale of shares ... the Company,s newly designated Series B Convertible Preferred ... expects to conduct a closing with respect to ...
(Date:8/15/2017)... 2017  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... beginning stages of an IPO. The United States ... average cost of a prescription epilepsy drug being $450.00-$1200.00 for a one ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion ...
(Date:8/11/2017)... 11, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it will release ... and host a conference call at 9:00am ET. The ... financial results and its strategy and outlook for the ... Erez Raphael , Chief Executive Officer, and ...
Breaking Medicine Technology: